Science Sub-Journal: A new longitudinal study documented COVID-19 antibody responses five months after symptoms appeared

11, 2020 /----- In a new study, researchers from Stanford University and other research institutions in the United States conducted a five-month longitudinal analysis of 254 patients with COVID-19 showing varying severity from asymptomatic to fatal diseases, showing that IGA and IgM antibodies for SARS-CoV-2 coronavirus disappeared rapidly during recovery.
study was published in the December 7, 2020 issue of the journal Science Immunology under the title "Defining the features and duration of antibody responses to SARS-CoV-2 infected with diseased severity and outcome."
by Scott D. Boyd of Stanford University School of Medicine.
first authors of the paper are Katharina Röltgen, Abigail E. Powell, Oliver F. Wirz and Bryan A. Stevens of Stanford University School of Medicine.
serological tests were performed on plasma from patients with a positive COVID-19 test result from SARS-CoV-2 rRT-PCR, pictured is Science Immunology, 2020, doi:10.1126/sciimmunol.abe0240.
Although IgG antibodies against SARS-CoV-2 may last longer, they record a slow, unstoppable decline in these antibodies, even in severe patients with very strong initial antibody responses.
by studying plasma samples collected from 79 hospitalized COVID-19 patients and 175 outpatients, as well asy as asymptomatic people infected with SARS-CoV-2, five months after infection, the researchers found that In patients with severe illness, the proportion of antibodies targeting this viral prickly protein (S protein) complex (as opposed to antibodies targeting this viral nucleoprotein) is higher in patients with mild illness, suggesting that the dominant position of these S-protein reactive antibodies may help alleviate the severity of symptoms.
To facilitate their research, the researchers also developed an immunometric method that can detect whether the interaction between the subject binding domain (RBD) of the SARS-CoV-2 virus S protein and the human ACE2 subject in human samples has been successfully blocked, providing an effective alternative to detection of positive antibodies.
the researchers say their findings could raise important questions about the reliability of sero-positive studies because the rapid decline in antibody titration may underestimate how many people in a given population may have been infected before.
they further note that "the decline in antibodies after infection also raises questions about how long the antibodies caused by vaccination will last and whether frequent increased vaccinations are needed to maintain this protective effect."
" (Bioon.com) Reference: 1. Katharina Röltgen et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science Immunology, 2020, doi:10.1126/sciimmunol.abe0240.2.New longitudinal study documents antibody responses to COVID-19 5 months after symptom onset。